United States: Supreme Court To Consider Federal Circuit De Novo Review Of Claim Construction In Teva Pharmaceuticals USA Inc. V. Sandoz Inc.

Last Updated: May 2 2014
Article by Martin L. Saad and Carly S. Levin

On March 31, 2014, the Supreme Court granted writ of certiorari in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. to hear Teva's appeal of a Federal Circuit decision invalidating several patents on Teva's multi-billion dollar multiple sclerosis drug, Copaxone.  The Supreme Court will address the Federal Circuit's standard of review of district court claim construction.  On appeal, the standard of review determines the amount of deference an appeals court will give in reviewing a lower court's decision.  Typically, an appeals court will review the lower court's factual findings for clear error, under Federal Rule of Civil Procedure 52(a).  Under the "clearly erroneous" standard, an appeals court will not overturn the lower court decision unless definitely and firmly convinced that the lower court made a mistake.  However, after its 1998 Cybor Corporation v. FAS Technologies, Inc. decision, the Federal Circuit reviews claim construction de novo.  Under de novo review, the appeals court gives no deference to the lower court's findings, and will rule on the evidence and matters of law as if considering them for the first time.  In Cybor Corp., the Federal Circuit held that "as a purely legal question, we review claim construction de novo on appeal including any allegedly fact-based questions relating to claim construction."  138 F.3d 1448, 1456 (Fed. Cir. 1998). 

In the Teva case, the Federal Circuit reversed the district court's claim construction determination on appeal.  The district court had construed the term "molecular weight" to refer to the peak average molecular weight of the claimed synthetic polypeptide.  The district court rejected defendants' argument that the claim term could refer to three different average molecular weight measures, and was therefore indefinite.  Instead, the lower court credited Teva's expert's testimony that a person of ordinary skill in the art would know to use the peak average molecular weight.  Teva Pharm. USA, Inc. v. Sandoz, Inc., 876 F. Supp. 2d 295, 400 –01 (S.D.N.Y. 2012) aff'd in part, rev'd in part, 723 F.3d 1363 (Fed. Cir. 2013) cert. granted, 13-854, 2014 WL 199529 (U.S. Mar. 31, 2014). 

On appeal, the Federal Circuit overturned the district court's finding of indefiniteness, noting that "[i]ndefiniteness is a question of law that we review de novo."  Teva Pharm. USA, Inc. v. Sandoz, Inc., 723 F.3d 1363, 1368 (Fed. Cir. 2013) cert. granted, 13-854, 2014 WL 199529 (U.S. Mar. 31, 2014).  Accordingly, the Federal Circuit considered Teva's expert's testimony along with the patent-in-suit's prosecution history, and found "[o]n de novo review of the district court's indefiniteness holding...[the expert] testimony does not save Group I claims from indefiniteness."  Id. at 1369.

Claim construction is a critical issue in almost every patent case.  The Federal Circuit's de novo review of claim construction may add a level of uncertainty to patent litigation, as a change in the way the court construes asserted patent claims can completely reverse the outcome of infringement and validity analyses. 

As Teva noted in its petition to the Supreme Court, the standard of review for claim construction is ripe for consideration after the Federal Circuit doubled down on de novo review by refusing to overturn the Cybor Corp. decision in Lighting Ballast Control LLC v. Philips Electronics North AmericaSee Reply Brief for Petitioners, Teva Pharms. USA, Inc. v. Sandoz, Inc., 723 F.3d 1363 (Fed. Cir. 2013) (No. 13-854), 2014 WL 768707, at *1.  In Lighting Ballast, after a jury trial, the district court entered judgment of infringement and validity.  On appeal, the Federal Circuit reversed, holding the claims invalid for indefiniteness.  Plaintiffs petitioned for rehearing en banc, and the Federal Circuit granted the petition in order to address whether the de novo standard for appellate review of district court claim construction decisions from Cybor Corp. should be overturned. 

In Lighting Ballast, both parties argued that the Cybor Corp. de novo standard of review is not appropriate for all aspects of claim construction in light of its fact-dependent nature.  Lighting Ballast advocated for the Federal Circuit to abandon de novo review completely because claim construction is a mixed question of fact and law.  Rehearing En Banc Response Brief of Plaintiff-Appellee, Lighting Ballast Control LLC v. Philips Elecs. N. Am. Corp., 744 F.3d 1272 (Fed. Cir. 2014) (No. 2012-1014), 2013 WL 3423281, at *24–25.  Universal Lighting argued that claim construction is a matter of law, and therefore de novo review is appropriate except where there are "disputed historical facts (if any)."  Rehearing En Banc Reply Brief of Defendant-Appellant, Lighting Ballast Control LLC v. Philips Elecs. N. Am. Corp., 744 F.3d 1272 (Fed. Cir. 2014) (No. 2012-1014), 2013 WL 3816455, at *5.  The Federal Circuit heard oral argument on September 13, 2013, to determine whether it should overrule Cybor Corp. and afford deference to any aspect of a district court's claim interpretation. 

On February 21, 2014, the Federal Circuit reconfirmed the de novo review standard for claim construction under Cybor Corp. in a fractured 6-4 decision.  The Federal Circuit provided several reasons in support of upholding Cybor Corp., noting that neither the Supreme Court nor Congress has provided authority post-Cybor Corp. to undermine its reasoning.  See Lighting Ballast Control LLC v. Philips Elecs. N. Am. Corp., 744 F.3d 1272, 1283 (Fed. Cir. 2014).  In addition, the Federal Circuit found no evidence in the fifteen years since Cybor Corp. was decided that the de novo standard of review is "unworkable." Id.  Furthermore, the Federal Circuit cited that the policy on uniformity concerns which underlies its Cybor Corp. decision remains in force, and no uniform proposal or alternative standard of review has been provided.  Id. at 1286.  The Federal Circuit stated that there is no evidence that deferential review would lead to "improved consistency" or "increased clarity" or that Cybor Corp. increased the burdens on the courts or litigants conducting claim construction.  Id.

Given these reasons, the Federal Circuit upheld Cybor Corp. and the de novo standard of review.  In dissent, Judge O'Malley, joined by Chief Judge Rader and Judges Reyna and Wallach, warned that "[c]onsiderations of stare decisis...do not justify adhering to precedent that misapprehends the Supreme Court's guidance, contravenes the Federal Rules of Civil Procedure, and adds considerable uncertainty and expense to patent litigation." Lighting Ballast, 744 F.3d at 1297 (O'Malley, J., dissenting).  Instead, "[w]hen a district court makes fact-findings needed to resolve claim construction disputes, Rule 52(a) requires us to defer to those findings unless they are clearly erroneous."  Id. at 1317. 

While the parties in Lighting Ballast have yet to petition for writ of certiorari, the Supreme Court will hear the same issues in the Teva case next term in October or November 2014.  In the meantime, Chief Justice John Roberts denied Teva's application for an order staying the Federal Circuit's ruling. Despite Teva's offer to post a $500 million bond if the Supreme Court would temporarily restore the district court's injunction, Chief Justice Roberts was "not convinced...that [Teva] has shown a likelihood of irreparable harm from denial of a stay" because Teva would be able to recover damages from the defendants for past patent infringement should it prevail in its appeal before the Supreme Court.  Teva Pharms. USA, Inc. v. Sandoz, Inc., No. 13A1003, 2014 WL 1516642 (U.S. Apr. 18, 2014).  Chief Justice Roberts' order clears the way for drug makers to launch generic versions of Copaxone in May.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions